San-Miguel JF, Gutierrez M-AE, Špicka I, Mateos M-V, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica 2018; 103(9):1518-1526; https://doi.org/10.3324/haematol.2017.185991.